Time in Range, Especially Overnight Time in Range, Is Associated With Sudomotor Dysfunction in Patients With Type 1 Diabetes

Zhou-qin Feng  
Nanjing Jinling Hospital: East Region Military Command General Hospital  
https://orcid.org/0000-0002-7995-352X

Qing-yu Guo  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Wei Wang  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Yan-yu Yuan  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Xu-guang Jin  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Hui Zhou  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Jun Liu  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Hai-yan Lei  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Xin-yi Yang  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Jun Liu  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Bin Lu  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Jia-qing Shao  
Department of Endocrinology, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University  
(✉️ shaojiaq@hotmail.com)

Ping Gu  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Research
Abstract

Background: To research the relationship between time in range (TIR) including overnight TIR and sudomotor function detected by SUDOSCAN in type 1 diabetes (T1D).

Methods: 95 patients with T1D were enrolled. TIR of 3.9-10.0 mmol/L was evaluated with CGM. SUDOSCAN measured feet electrochemical skin conductance (FESC) and sudomotor dysfunction was defined as average FESC<60µS. Logistic regressions were applied to examine the independent association of TIR and overnight TIR with sudomotor function.

Results: The overall prevalence of sudomotor dysfunction was 28.42%. Patients with sudomotor dysfunction had significantly lower TIR for the whole recorded phase and for nighttime. The sudomotor dysfunction prevalence progressively declined with the ascending tertiles of TIR and nocturnal TIR (P for trend <0.05). Correlation analysis showed that the relationship between nocturnal TIR and FESC was stronger than that between TIR and FESC with correlation coefficient was respectively 0.362 and 0.356 (P <0.001). Finally, logistic regression analysis indicated the independently negative relation between TIR and nocturnal TIR and sudomotor dysfunction (P <0.05), notably, more statistically significant results were obtained between nocturnal TIR and sudomotor dysfunction.

Conclusions: TIR is negatively correlated with sudomotor dysfunction in T1D independent of HbA1c. Furthermore, decreased nocturnal TIR is more closely related to the impaired function of sudomotor nerves in sweat glands.

1. Background

We are facing an epidemic of diabetes, the number of diabetes is expected to increase by 2045 to 700 million worldwide [1]. As one of the most common microvascular complications of diabetes, diabetic peripheral neuropathy (DPN) is the most critical initial risk factor for diabetic foot and amputation and affects more than 50% of individuals with type 1 diabetes(T1D) or type 2 diabetes(T2D) [2]. According to the World Health Organization, the incidence of lower limb amputation in patients with diabetes is ten times that of non-diabetic patients [3]. It is remarkably, the secretory function of sweat gland, controlled by thin unmyelinated sympathetic C nerve fibers, is pretty vulnerable in the process of diabetes [4]. And sudomotor function, which noninvasively measures early neurophysiologic abnormalities of peripheral nerve fiber via analyzing sweat production or sweat chloride concentrations, have been recommended to mirror early neuropathy by the American Association of Clinical Endocrinologists guidelines in 2015 [5]. Thus, early identification and intervention are the best way to prevent or halt DPN and its devastating sequelae.

Hyperglycemia accounts for the emergence of neuropathy in patients with T1D [6], hence needing good glycemic control for these people. Usually, we take hemoglobin A1c (HbA1c) as the standard for glucose. However, HbA1c may be unreliable for the reason that it misses the information about hypoglycemia,
glycemic variability or the daily mode of blood sugar [7]. Peculiarly, the blood sugar is prone to fluctuate in T1D.

Continuous glucose monitoring (CGM) technologies provide the preferable mean to capture glucose trends and glucose variability than HbA1c nowadays. Among CGM derived metrics, ‘time in ranges’ encompassing time in target range of 3.9–10 mmol/L (TIR), time above range of 10mmol/L (TAR) as well as time below range of 3.9 mmol/L (TBR) are in the spotlight. ‘Time in ranges’ can reflect short-run glycemic control intuitively [8]. Published data revealed a substantial correlation between TIR and HbA1c [9, 10]. Based on extensive clinical evidence, American Diabetes Association guidelines for 2020 advocated TIR should be accepted as a clinical endpoint and an emerging metric for assessment of glycemic control [11]. TIR complements information obtained from HbA1c measurements for identifying patients who have the risk of microvascular complications of diabetes [12], whereas there is little report of the impact of TIR on early DPN in T1D. Moreover, nocturnal glycemic control is proven to be associated with adverse diabetic outcomes [13, 14], and to our knowledge, studies on nocturnal TIR and diabetic complications are lacking.

SUDOSCAN measures sudomotor function quantitatively, and this approach has the advantages of safety, high efficiency and objectivity [15]. Here, we set about to research the relationship between TIR including overnight TIR and sudomotor function detected by SUDOSCAN with the intention of exploring the correlation of TIR including overnight TIR and early DPN in T1D.

2. Materials And Methods

2.1. Research objects

We included 95 individuals with T1D who were hospitalized to better control their blood sugar. These patients both wore 72h CGM (Meiqi Corporation) and underwent sudomotor function test during their hospitalization at the endocrinology department of the Jinling Hospital, the First School of Clinical Medicine, Southern Medical University from October 2018 to July 2020. T1D was diagnosed in line with the criteria of World Health Organization (WHO) in 1999. At the time of study, these patients followed their usual regimen of insulin pump or multiple daily subcutaneous insulin injection (MDSI). Exclusion criteria included: (1) An acute condition requiring intervention such as ketoacidosis, hypoglycemic coma; (2) Secondary neurological impairment result from drugs, alcoholism, vitamin B12 deficiency or thyroid disease and so on. We got approved from local ethics committee and all participants were given informed consent.

2.2. Clinical and biochemical information

We obtained information of general clinical characteristics from the electronic medical records system. Physical measurements consist of age, gender, diabetes duration, height, weight, Systolic blood pressure(SBP), diastolic blood pressure (DBP), diabetic complications, and status of insulin administration. Body mass index (BMI) was calculated as weight (kg)/height (m)^2. Laboratory
examinations including hemoglobin A1C (HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), serum albumin (Alb), serum urea nitrogen (BUN), and serum creatinine (Scr), uric acid (UA). HbA1c was determined by high performance liquid chromatography (HLC-723G8 Automatic glycosylated hemoglobin Analyzer, TOSOH, Japan). All the above biochemical indices were tested under fasting conditions for more than 10 hours. Previous or present smokers were considered to have smoked. Criteria for diagnosing diabetic nephropathy (DN) was based on urinary albumin-to-creatinine ratio (ACR) being over 30mg/g by at least two examinations. Diabetic retinopathy (DR) was determined by the same ophthalmologist through fundus examination and stereofundus photography after pupillary dilation.

2.3. CGM metrics calculation

During the wearing-period of CGM for three days, a skillful nurse was informed to correct the instrument via entering capillary blood glucose measurements more than four times per day. 288 continuous glucose values were recorded daily. After 72-hour recording, all data were acquired retrospectively. Software Easy GV Version 9.0R2 from Oxford University was used to calculate the measurements representing blood glucose variability (GV), including M value, average daily risk range (ADDR), amplitude of glucose excursions (MAGE), standard deviation (SD), and coefficient of variation (CV). TIR represented the percentage of time blood sugar reached the level of 3.9–10 mmol/L. TBR represented the percentage of time blood sugar below the level of 3.9 mmol/L. TAR represented the percentage of time blood sugar above the level of 10 mmol/L. Nocturnal ‘time in ranges’ were defined as percentage of time blood sugar reached the corresponding level between 00:00 and 6:00 A.M (6 h). Our calculations were the inclusion of all data within 72 hours.

2.4. Sudomotor function evaluation

On the afternoon of the hospitalization the sudomotor testing was done. SUDOSCAN (Impeto Medical, Paris, France) consists of two sets of stainless steel electrodes for the hands and feet that are connected to a computer for recording and data output. At machine start, patients were told to place their palms of their hands and the soles of their feet on the electrodes and a current incremental voltage of 4 V is applied after around 2–3 min. The main output of the machine that we care are electrochemical skin conductance (ESC) of hands and feet. Lower ESC value means worse sudomotor function. On the basis of ESC (use µS said) measured on the feet, we set the FESC equal to 60 µS as the cut-off point for grouping^{16}. So the study patients was divided into normal sudomotor function group (FESC ≥ 60µS) and sudomotor dysfunction group (FESC < 60µS).

2.5. Statistical analysis

Data analysis were performed with SPSS 25.0. Continuous data with normal distribution were expressed in mean ± SD, those with skewed distribution were expressed in median (interquartile). Categorical data were expressed in count (percentages). Between-group comparisons were conducted by statistical methods like Student’s t-test, the Mann-Whitney test, and the chi-squared test. In the light of the distribution characteristics of the data, Pearson correlation analysis and Spearman correlation analysis
were separately adopted to identify the relationships between variables. The binary logistic regression analysis and the linear regression analysis with FESC as a categorical variable or continuous variable were applied to examine the independent correlation between TIR and sudomotor function. Odds ratios (ORs) and 95% confidence intervals were listed. \( P < 0.05 \) was of statistically significance.

3. Results

3.1 Clinical characteristics of the study object

Our study of the 95 patients with T1DM, 74.74% were male, showed a mean age of 36(27,52) years, mean BMI of \( 21.77 \pm 3.11 \text{ kg/m}^2 \), median diabetes course of 4 (1,10) years, mean HbA1c level of \( 9.78 \pm 2.44\% \). The overall incidence rate of sudomotor dysfunction was prevalent in 28.42% of study patients. As illustrated by Table 1, the majority of baseline characteristics of people in the sudomotor dysfunction group paralleled those of the normal sudomotor function group except for blood urea nitrogen, serum albumin and the prevalence of diabetic nephropathy. Patients with sudomotor dysfunction had a higher level of blood urea nitrogen, a bigger proportion of suffering from diabetic nephropathy (DN) and a lower level of serum albumin (all \( P < 0.05 \)).
| Character            | Total (N = 95) | Sudomotor dysfunction (+) group (N = 27) | Sudomotor dysfunction (-) group (N = 68) | P value |
|----------------------|---------------|-----------------------------------------|------------------------------------------|---------|
| Age (y)              | 36.00(27.00,52.00) | 35.50(25.25,51.75) | 39.00(31.00,54.00) | 0.256   |
| Male (n, %)          | 71(74.74%) | 21(77.78%) | 50(73.53%) | 0.667   |
| BMI (kg/m²)          | 21.77 ± 3.11 | 21.06 ± 3.27 | 22.06 ± 3.03 | 0.160   |
| DM duration (y)      | 4.00(1.00,10.00) | 7(0.5,14.00) | 4.00(1.00,8.00) | 0.252   |
| SBP (mmHg)           | 126.00(120.00,132.00) | 130.00(120.00,140.00) | 125.00(119.25,131.00) | 0.222   |
| DBP (mmHg)           | 76.00(70.00,83.00) | 75.00(70.00,87.00) | 76.50(71.00,83.00) | 0.987   |
| BUN (mmol/L)         | 5.77 ± 2.28 | 6.71 ± 3.51 | 5.40 ± 1.44 | 0.012   |
| Scr (µmol/L)         | 56.50(45.18,66.85) | 59.40(46.00,73.70) | 56.00(44.50,65.00) | 0.460   |
| UA (µmol/L)          | 280.63 ± 107.42 | 265.33 ± 104.78 | 286.89 ± 108.65 | 0.382   |
| TC (mmol/L)          | 4.43 ± 0.97 | 4.21 ± 0.83 | 4.52 ± 1.01 | 0.166   |
| TG (mmol/L)          | 0.93(0.65,1.33) | 0.97(0.69,1.46) | 0.88(0.65,1.24) | 0.610   |
| HDL (mmol/L)         | 1.36 ± 0.40 | 1.30 ± 0.39 | 1.39 ± 0.41 | 0.394   |
| LDL (mmol/L)         | 2.62 ± 0.81 | 2.50 ± 0.78 | 2.67 ± 0.82 | 0.364   |
| Alb (g/L)            | 38.00(34.30,40.80) | 36.30(31.30,39.30) | 38.30(35.98,41.53) | 0.014   |
| HbA1c (%)            | 9.78 ± 2.44 | 9.94 ± 2.79 | 9.70 ± 2.30 | 0.672   |
| Smoking (%)          | 30(31.58%) | 12(44.44%) | 18(26.47%) | 0.089   |
| Retinopathy (n, %)   | 20(21.05%) | 8(29.63%) | 12(17.65%) | 0.196   |

Data are presented as means ± SD, median (25% and 75% interquartiles), and count (percentages) according to characteristics of distribution. Between-group comparisons were conducted by Student’s t-test, the Mann-Whitney test, and the chi-squared test.

**Abbreviations:** BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; Scr, serum creatinine; UA, uric acid; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Alb, serum albumin; HbA1c, hemoglobin A1c; MDSI, multiple daily subcutaneous injection.
Glycemic parameters were enumerated in the Table 2. Subjects in sudomotor dysfunction group had significantly lower TIR and higher TAR for the whole recorded phase and for nighttime, as well as bigger M value and ADDR. Subjects without sudomotor dysfunction had higher TBR and overnight TBR (all $P < 0.05$).
### Table 2
CGM glucometrics according to sudomotor function

| CGM glucometrics | Total (N = 95) | Sudomotor dysfunction (+) group (N = 27) | Sudomotor dysfunction (-) group (N = 68) | \( P \) value |
|------------------|----------------|-----------------------------------------|-----------------------------------------|---------------|
| Whole recorded phase (3 days) | | | | |
| TBR (%) | 0.00 (0.00, 1.35) | 0.00 (0.00, 0.00) | 0.11 (0.00, 2.26) | 0.005 |
| TIR (%) | 46.41 ± 24.27 | 36.25 ± 25.08 | 50.44 ± 22.90 | 0.009 |
| TAR (%) | 49.32 ± 25.85 | 60.19 ± 26.72 | 45.00 ± 24.37 | 0.009 |
| Mean (mmol/L) | 10.64 ± 2.60 | 11.93 ± 3.10 | 10.13 ± 2.20 | 0.009 |
| M value (mmol/L) | 16.56 (9.20, 33.18) | 23.70 (13.15, 59.56) | 14.56 (8.84, 27.00) | 0.024 |
| ADDR | 35.17 ± 14.8 | 41.41 ± 18.55 | 32.66 ± 12.37 | 0.030 |
| MAGE (mmol/L) | 5.09 ± 2.49 | 4.95 ± 2.49 | 5.14 ± 2.51 | 0.735 |
| SD (mmol/L) | 3.62 ± 1.28 | 3.72 ± 1.15 | 3.58 ± 1.33 | 0.636 |
| CV (%) | 34.58 ± 11.35 | 32.06 ± 10.70 | 35.59 ± 11.53 | 0.174 |
| Overnight phase (0:00 – 6:00 am) | | | | |
| TBR (%) | 0.00 (0.00, 3.33) | 0.00 (0.00, 0.00) | 0.00 (0.00, 5.63) | 0.013 |
| TIR (%) | 64.72 (34.17, 88.33) | 38.61 (2.22, 69.72) | 67.64 (48.26, 90.35) | 0.004 |
| TAR (%) | 33.33 (5.28, 57.22) | 59.72 (18.44, 97.98) | 29.72 (2.85, 47.64) | 0.001 |

Data are presented as means ± SD, median (25% and 75% interquartiles), and count (percentages) according to characteristics of distribution. Between-group comparisons were conducted by Student’s t-test and the Mann-Whitney test.

**Abbreviations**: TBR, time below range; TIR, time in range; TAR, time above range; Nocturnal TIR was defined as percentage of time blood sugar reached the level of 3.9–10 mmol/L between 00:00 and 6:00 A.M (6 h). Nocturnal TBR was defined as percentage of time blood sugar below the level of 3.9–10 mmol/L between 00:00 and 6:00 A.M (6 h). Nocturnal TAR was defined as percentage of time blood sugar above the level of 3.9–10 mmol/L between 00:00 and 6:00 A.M (6 h); ADDR, average daily risk range; MAGE, amplitude of glucose excursions; SD, standard deviation; CV, coefficient of variation.

### 3.2 Prevalence of sudomotor dysfunction among groups according to tertiles

Because of the extremely low frequency of TBR and overnight TBR in our research, we just included TIR, TAR, nocturnal TIR and nocturnal TAR for analysis. As shown in Fig. 1, these target metrics were all...
stratified by tertiles. As for TIR and nocturnal TIR, the prevalence of sudomotor dysfunction decreased with increasing tertiles (all $P$ for trend < 0.05). The sudomotor dysfunction prevalence was higher in patients in the first tertile of TIR (41.9%) than that in the second (26.5%) and the third (16.7%). Prevalence rates from the bottom tertile to the top tertile of nocturnal TIR were 48.4%, 21.2%, and 16.1%. Picture b and d depicted the prevalence of sudomotor dysfunction was higher in the highest tertile of TAR (43.8%) and nocturnal TAR (53.3%) than in the lower tertiles of TAR and nocturnal TAR.

3.3 Correlation between CGM data and the other clinical index and ESC

Through the Pearson correlation analysis and the Spearman's correlation analysis, we found a significant positive correlation between TIR, TBR, nocturnal TIR and nocturnal TBR and FESC ($r = 0.356$, $r_s = 0.356, 0.397, 0.362, 0.311$, respectively, $P < 0.05$). TAR and nocturnal TAR were found to negative associated with FESC ($r = -0.391$, $r_s = -0.405$, respectively, $P < 0.05$). Bigger HESC showed inverse correlation with TAR ($r = -0.208$, $P < 0.05$). M value and ADDR also had obviously negative concerning with FESC ($r_s = -0.307$, $r = -0.375$, respectively, $P < 0.05$). Serum albumin had positive association with FESC and HESC ($r_s = 0.271, 0.248$, respectively, $P < 0.05$). DN had negative association with FESC and HESC ($r = -0.281, -0.246$, respectively, $P < 0.05$). There was no influence of blood urea nitrogen had on FESC and HESC (Table 3).
Table 3
Correlations of glycemic metrics and other clinical variables and ESC.

|               | FESC          | HESC          |
|---------------|---------------|---------------|
|               | r/ rₚ         | P             | r/ rₚ         | P             |
| TBR           | 0.397         | < 0.001       | 0.185         | 0.073         |
| TIR           | 0.356         | < 0.001       | 0.189         | 0.067         |
| TAR           | -0.391        | < 0.001       | -0.208        | 0.043         |
| Nocturnal TBR | 0.311         | 0.002         | 0.104         | 0.315         |
| Nocturnal TIR | 0.362         | < 0.001       | 0.156         | 0.132         |
| Nocturnal TAR | -0.450        | < 0.001       | -0.177        | 0.086         |
| M value       | -0.307        | 0.002         | -0.185        | 0.072         |
| ADDR          | -0.375        | < 0.001       | -0.157        | 0.131         |
| BUN           | -0.168        | 0.110         | -0.191        | 0.068         |
| Alb           | 0.271         | 0.008         | 0.248         | 0.016         |
| Nephropathy   | -0.281        | 0.006         | -0.246        | 0.016         |

Pearson (r) or Spearman (rₛ) correlations were used to investigated associations between variables.

**Abbreviations**: TBR, time below range; TIR, time in range; TAR, time above range; Nocturnal ‘time in ranges’ were defined as percentage of time blood sugar reached the corresponding level between 00:00 and 6:00 A.M (6 h); FESC, feet electrochemical skin conductance; HESC, hand electrochemical skin conductance; Alb, serum albumin; BUN, blood urea nitrogen; ADDR, average daily risk range; CV, coefficient of variation.

### 3.4. Binary logistic regression analysis of FESC as a categorical variable

Table 4 interpreted that TIR and overnight TIR were significantly associated with risk of abnormal sudomotor function on binary logistic regression analysis. The OR for the risk of sudomotor dysfunction was respectively 0.974 (95% CI: 0.955–0.994) and 0.977 (95% CI: 0.963–0.992) per 10% increase in TIR and overnight TIR in the crude model. After adding compounding variables including sex, age, diabetes duration, BMI, Alb, smoking, BUN, and DN, the relationship between TIR and overnight TIR and sudomotor dysfunction did not change (all P < 0.05). We added HbA1c in the model 3 of the binary logistic regression, the similar result was observed (P < 0.05). Notably more statistically significant results were obtained between nocturnal TIR and sudomotor dysfunction. Apart from that, M value was positively associated with risk of abnormal sudomotor function in both the pre- and post-adjustment models. ADDR was
statistically associated with sudomotor dysfunction only in the crude logistic model, as shown in the Table 4.

| Parameters | OR    | 95%CI         | P   |
|------------|-------|---------------|-----|
| TIR        |       |               |     |
| Crude      | 0.974 | 0.955 to 0.994 | 0.012 |
| Model 1    | 0.975 | 0.953 to 0.998 | 0.031 |
| Model 2    | 0.975 | 0.951 to 0.999 | 0.041 |
| Model 3    | 0.975 | 0.951 to 1.000 | 0.047 |
| Nocturnal TIR |     |               |     |
| Crude      | 0.977 | 0.963 to 0.992 | 0.002 |
| Model 1    | 0.979 | 0.963 to 0.996 | 0.016 |
| Model 2    | 0.979 | 0.961 to 0.997 | 0.024 |
| Model 3    | 0.980 | 0.962 to 0.998 | 0.028 |
| M value    |       |               |     |
| Crude      | 1.036 | 1.012 to 1.061 | 0.003 |
| Model 1    | 1.041 | 1.012 to 1.071 | 0.005 |
| Model 2    | 1.040 | 1.010 to 1.070 | 0.008 |
| Model 3    | 1.042 | 1.012 to 1.074 | 0.007 |
| ADDR       |       |               |     |
| Crude      | 1.041 | 1.009 to 1.074 | 0.012 |
| Model 1    | 1.036 | 0.999 to 1.075 | 0.054 |
| Model 2    | 1.036 | 0.998 to 1.075 | 0.064 |
| Model 3    | 1.039 | 0.999 to 1.080 | 0.056 |

Crude was not adjusted;
Model 1 was adjusted for sex, age, diabetes duration, BMI, Alb, smoking;
Model 2 was adjusted for all variables in Model 1 plus BUN, DN;
Model 3 was adjusted for all variables in Model 2 plus HbA1c;
3.5. Multiple linear regression analysis of FESC as a continuous variable

Liner regression analysis described a stable linear association of TIR and nocturnal TIR with FESC. TIR as well as nocturnal TIR were positively correlated with FESC in both the crude and adjusted models including sex, age, diabetes duration, BMI, Alb, smoking, BUN, DN and HbA1c (all $P < 0.05$) (Table 5). We also noticed a more statistically significant results between nocturnal TIR and FESC.

Table 5
Association of TIR and overnight TIR with FESC by linear regressions.

| Models   | $\beta$   | 95% CI      | $P$       |
|----------|-----------|-------------|-----------|
| TIR      | Crude     | 0.359       | 0.165 to 0.553 | < 0.001 |
|          | Model 1   | 0.329       | 0.132 to 0.527 | 0.001   |
|          | Model 2   | 0.306       | 0.1187 to 0.496 | 0.002   |
|          | Model 3   | 0.263       | 0.063 to 0.462 | 0.011   |
| Nocturnal TIR | Crude | 0.317       | 0.175 to 0.458 | < 0.001 |
|          | Model 1   | 0.253       | 0.106 to 0.400 | 0.001   |
|          | Model 2   | 0.246       | 0.099 to 0.393 | 0.001   |
|          | Model 3   | 0.226       | 0.073 to 0.378 | 0.004   |

Crude was not adjusted;
Model 1 was adjusted for sex, age, diabetes duration, BMI, Alb, smoking;
Model 2 was adjusted for all variables in Model 1 plus BUN, DN;
Model 3 was adjusted for all variables in Model 2 plus HbA1c;

4. Discussion

In our study cohort of 95 adult individuals with T1D, patients with sudomotor dysfunction had features of lower TIR and nocturnal TIR, higher TAR and nocturnal TAR in comparison with patients without sudomotor dysfunction. Group patients by tertiles of TIR and nocturnal TIR, we found the prevalence of sudomotor dysfunction decreased with increasing tertiles. Correlation analysis revealed that the relationship between nocturnal TIR and FESC was stronger than that between TIR and FESC with correlation coefficient was respectively 0.362 and 0.356. Multiple regression analysis revealed that both TIR and nocturnal TIR were inversely associated with the risk of sudomotor dysfunction detected by
SUDOSCAN regardless of sex, age, diabetes duration, BMI, Alb, smoking BUN, DN and HbA1c, notably, more statistically significant results were obtained between nocturnal TIR and sudomotor dysfunction.

DPN is characterized by broad spectrum of clinical presentations and can stay asymptomatic for a long time, that hinder the prompt diagnosis of this disease [17]. And meanwhile, it is sad to say that the measures we use for detection of DPN in routine clinical practice either are crude, or detect the disease very late when DPN has been well established. For example, scored clinical assessments such as the Michigan Neuropathy Screening Instrument (MNSI), the Neuropathy Impairment Score (NIS), and the Neuropathy Disability Score (NDS), remain subjective, heavily reliant on the examiners’ interpretations [18]. Besides, tests purport to diagnose DPN—including the 10 g monofilament, the Ipswich Touch Test, and vibration perception threshold testing—are still dependent on patients’ subjective response [19]. Although nerve conduction studies (NCS) are the current sensitive and specific tool for DPN, they are not only labour intensive, time consuming, and costly, but are also just an assessment of large nerve fibers function [20].

Small nerve fibers, which account for 70–90% of the peripheral nerve fibers, have been proved to be the first damaged part with skin biopsies by assessing intraepidermal nerve fiber density (IENFD), including the fibers that innervate the sweat glands [21]. Thus, sudomotor function represents an attractive tool to evaluate early neuropathy in people with DM. SUDOSCAN is an FDA approved point of care device which provides a quantitative measurement of sudomotor function within 3 min [22]. Solomon et al. assessed the diagnostic performance of SUDOSCAN for DPN in T1DM. Their study defined DPN in terms of established American Academy of Neurology consensus criteria using NCS and clinical examinations and found that the sensitivity and specificity of FESC were respectively 87.5 % and 76.2 % with the area under the ROC curve (AUC) was 0.85 [23]. Jin et al. also explored the diagnostic efficiency of SUDOSCAN in Chinese with a sensitivity and specificity of 85.6% and 76.2 % (AUC = 0.859) [24]. In addition, study also showed the robust repeatability and reproducibility of this machine in person with or without diabetes [25].

A series of large studies evidenced that blood sugar management, as represent by HbA1c, is an effective method for reducing the occurrence or progression of DPN in T1DM. During the mean 6.5-year follow-up, the Diabetes Control and Complications Trial (DCCT) concluded that the prevalence of DPN increased substantially in the conventional participants (from 5 % to 17 %) and only slightly among the intensive group participants (from 7 % to 9 %) with HbA1c values between the two groups were 9.1% and 7.4%, respectively. Adjusting for the presence of confirmed DSP at baseline, the risk reduction for incident DSP with intensive glucose control during DCCT was 64 % [26]. The European Diabetes (EURODIAB) Prospective Complications Study confirmed that HbA1c level during follow-up contributed especially to the risk of neuropathy, independently of the baseline HbA1c [27]. However, we should not ignore the reality that in DCCT the cumulative incidence of neuropathy (15–21%) and abnormal nerve conduction (40% to 52 %) remained substantial [28]. Besides, through 14 years of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, 25% of subjects in the former intensive treatment group and 35% of
subjects in the former conventional therapy group developed confirmed DPN [29]. Such thought-provoking results hint that neuropathy can develop even the ‘ideal glycemic control’ tested by HbA1c.

HbA1c estimates blood glucose concentrations over 2–3 months, but fails to predict the day-to-day glucose excursions [10]. Beck et al. re-analyzed the DCCT’s data to search for the role TIR played in diabetic microvascular outcomes. They found TIR was higher in the intensively treated group than in the conventionally treated group (52 vs. 31%), the per 10% decrease in TIR led to a 64% raise in retinopathy and a 40% increase in microalbuminuria, though resources are a 7-point glucose profile from capillary blood [30]. Our study showed that abnormal sudomotor function group had perceptibly lower TIR and nocturnal TIR, higher TAR, nocturnal TAR, M value and ADDR, while HbA1c level between groups was comparable (9.94 ± 2.79% vs. 9.70 ± 2.30%; P = 0.672). Above calculated results signified that HbA1c may be inferior to CGM metrics in building relationships with sudomotor dysfunction. Importantly, comparisons of groups expressing similar HbA1c values but different short-term glucose fluctuation values and ‘time in ranges’ may be helpful to establish the role of these dysglycemia components in DPN.

When it comes to people with T2D, former studies documented that TIR derived from data of CGM has a significantly positive correlation with peripheral nerve function [31], a significantly negative correlation with painful diabetic polyneuropathy [32]. Moreover, our previous work demonstrated a negative correlation between TIR and sudomotor dysfunction in T2D [16]. Consistent with those findings, we now observed the prevalence of abnormal sudomotor function in the study population declined with the ascending of TIR tertiles. The linear and binary logistic regression analysis both indicated the independently negative association between TIR and sudomotor dysfunction even after adjusting for several risk factors.

Overnight glycemic control turns out to be a portion linked with the risk of diabetes outcomes. A prospective observational study was conducted on 162 pregnant women with gestational diabetes mellitus to investigate the association between temporal change of glucose and large for gestational age (LGA) infants [13]. By analysis of 7-day CGM data, the authors summarized that individuals who delivered LGA infants underwent significantly higher glucose concentrations during the 6-hour period of the night (00:00–06:00 am) compared with mothers who did not have LGA infants (6.0 ± 1.0 mmol/L vs. 5.5 ± 0.8 mmol/L; P = 0.005) [13]. Another research found mean nocturnal glucose levels, rather than diurnal glucose values or glucose variability, were independently related to the seriousness of vascular remodeling [14]. For the first time, based on the results of data analysis, we draw a conclusion that overnight TIR assured of its place in sudomotor dysfunction. Possible explanations for patients with suboptimal overnight TIR may lies in: (1) the overnight period lacks the glycemic excursions due to meals and exercise that occurs during the day; (2) under normal conditions of nighttime sleep, the elevated levels of growth hormone and cortisol cause the increment of the blood glucose [33]; (3) our selected samples were patients who just came to the hospital for undesirable glycemic control in the past. One can saw this with the mean level of HbA1c was more than 9% in study objects.

Explaining exact mechanisms of the above scenario are difficult, however, we can try to understand it with rational speculation. Clinical evidences suggest that overnight glycaemic control is susceptible to the
daytime blood sugar levels of the person with diabetes and vise versa [34]. Poor nocturnal glycemic control can cause a reduced sensitivity of insulin at liver and other tissues, leading to fasting hyperglycemia [35]. Fasting blood glucose is the cornerstone of all-round glycemic control throughout the day. So we guess that lower TIR in the overnight period exacerbates the whole-day TIR thereby exert an influence on diabetic outcomes. Anyway our result extends the clinical benefits of TIR by demonstrating that nocturnal TIR is also involved in diabetes outcomes.

Given that GV is involved in the natural process of DPN in subjects with T1D [36] and we used to verify M value contributed to sudomotor dysfunction in T2D [14], we also analysed the effect that M value, ADDR, MAGE, SD and CV, as an index of short-term GV, had on DPN, represented by abnormal sudomotor function. Again M value was proved to be a strong and stable predictive element for sudomotor dysfunction in T1D. By contrast, the other indicators are less effective predictors. ADDR was statistically associated with sudomotor dysfunction in the crude logistic model, but after adjustment of several confounding factors like sex, age, diabetes duration, BMI, Alb, smoking, BUN, DN, and HbA1c, the relationship was inexistent with borderline significance. MAGE, SD and CV showed no relationship with sudomotor function firmly (data not shown).

Our study had a certain degree of limitation. In essence, this retrospective study cannot draw a cause-and-effect conclusion but can only describe the correlation between TIR and sudomotor function. Apart from that, all participants received 3 d of CGM, which perhaps made our results unrepresentative. Last but not least, despite relatively small number of samples in our cohort, patients with T1D are often regarded more homogeneous than patients with T2D. These people usually lack the other components of metabolic disorder so common for patients with T2D [37]. And we strictly conformed to inclusion and exclusion criteria to avoid the baseline characteristics of subjects vary enormously, which facilitates the chance of disclosing an association between CGM glucometrics and early diabetic complications in T1D.

5. Conclusions

To sum up, TIR is negatively correlated with sudomotor dysfunction in type 1 diabetes independent of HbA1c. Furthermore, decreased nocturnal TIR is more closely related to the impaired function of sudomotor nerves in sweat glands. Therefore, there's a reasonable prospect that optimizing TIR and, more importantly, highlighting the management of nocturnal TIR may help reduce rates of early DPN in T1D, yet prospective studies are awaited to further testify it.

Abbreviations

T1D: type 1 diabetes; DPN: diabetic peripheral neuropathy; CGM: Continuous glucose monitoring; DN: diabetic nephropathy; DR: diabetic retinopathy; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; BUN: blood urea nitrogen; Scr: serum creatinine; UA: uric acid; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Alb: serum albumin; HbA1c: hemoglobin A1c; MDSI: multiple daily subcutaneous injection; TBR: time below range;
TIR: time in range; TAR: time above range; ADDR: average daily risk range; MAGE: amplitude of glucose excursions; SD: standard deviation; CV: coefficient of variation; AUC: area under the curve.

Declarations

Ethics approval and consent to participate

Approval was obtained from the ethics committee of Southern Medical University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

There are no conflicts of interest.

Funding

This work was supported by the National Natural Science Foundation of China (grant No.81774134, No.81873174), Natural Science Foundation of Jiangsu Province of China (grant No.BK20171331), Postdoctoral Foundation of Jiangsu Province of China (grant No.1501120C), Young Medical Key Talents Project of Jiangsu Province (grant No.QNRC2016902), Jiangsu Province 333 Talent Funding Project (grant No.BRA2017595), as well as Key Research and Development Plan Project of Jiangsu Province - Social Development Projects(grant No.BE2020701).

Authors’ contributions

Zhou-qin Feng, Qin-yu Guo and Wei Wang projected the research. Zhou-qin Feng, Xu-guang Jin, Hui Zhou and Jun Liu were in charge of data collection. Zhou-qin Feng, Jun Liu and Bin Lu analyzed and interpreted the data. Zhou-qin Feng, Yan-yu Yuan and Hai-yan Lei executed the statistical analysis. Zhou-qin Feng wrote the manuscript. Ping Gu and Jia-qing Shao critically revised the manuscript for key intellectual content. Zhou-qin Feng are responsible for the integrity of the work. All authors read and approved the final manuscript. Zhou-qin Feng, Qin-yu Guo and Wei Wang contributed equally to the paper.

Acknowledgements
The authors are very thankful to forward their gratitude to the data collectors, supervisor, study subjects for their cooperation.

References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019 Nov;157:107843.

2. Yang Z, Xu B, Lu J, et al. Autonomic test by EZSCAN in the screening for prediabetes and diabetes PLoS One 2013;8.

3. Hoffstad O, Mitra N, Walsh J, Margolis DJ. Diabetes, lower-extremity amputation, and death. Diabetes Care 2015;38(10):1852-1857.

4. Selvarajah D, Cash T, Davies J, et al. SUDOSCAN: A Simple, Rapid, and Objective Method with Potential for Screening for Diabetic Peripheral Neuropathy. PLoS One 2015;10(10): e0138224.

5. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21 Suppl 1:1-87.

6. Beck RW, Connor CG, Mullen DM, et al. The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading. Diabetes Care 2017;40(8):994-999.

7. Beck RW, Bergenstal RM, Riddlesworth D, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 2019;42(3):400- 405.

8. Advani A. Positioning time in range in diabetes management. Diabetologia 2020;63(2):242-252.

9. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 2019;13:614–626

10. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019;21: 81–85.

11. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020 Jan;43(Suppl 1): S66-S76.

12. Ranjan AG, Rosenlund SV, Hansen TW, et al. Improved Time in Range Over 1 Year Is Associated with Reduced Albuminurira in Individuals with Sensor- Augmented Insulin Pump-Treated Type 1 Diabetes. Diabetes Care 2020;43(11):2882-2885.

13. Law GR, Alnaji A, Alrefaii L, et al. Suboptimal Nocturnal Glucose Control Is Associated with Large for Gestational Age in Treated Gestational Diabetes Mellitus.Diabetes Care 2019;42(5):810-815.

14. Yano Y, Hayakawa M, Kuroki K, et al. Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients. Atherosclerosis 2013;227(1):135-139.

15. Ang L, Jaiswal M, Martin C, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 2014;14(9):528.
16. Guo QY, Lu B, Guo ZH, et al. Continuous glucose monitoring defined time-in-range is associated with sudomotor dysfunction in type 2 diabetes. World J Diabetes 2020;11(11):489-500.

17. Mao F, Liu S, Qiao X, et al. Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in Chinese type 2 diabetes mellitus patients. J Diabetes Investig 2017;8(3):363-368.

18. Burgess J, Frank B, Marshall A, et al. Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres. Diagnostics (Basel) 2021;11(2):165.

19. Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 2019;7(12):938-948.

20. Iqbal Z, Azmi S, Yadav R, et al. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clin Ther 2018;40(6):828-849.

21. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014 Jul;63(7):2454-63.

22. Chahal S, Vohra K, Syngle A. Association of sudomotor function with peripheral artery disease in type 2 diabetes. Neurol Sci 2017;38(1):151-156.

23. Selvarajah D, Cash T, Davies J, et al. SUDOSCAN: A Simple, Rapid, and Objective Method with Potential for Screening for Diabetic Peripheral Neuropathy. PLoS One 2015;10(10): e0138224.

24. Jin J, Wang W, Gu T, et al. The Application of SUDOSCAN for Screening Diabetic Peripheral Neuropathy in Chinese Population. Exp Clin Endocrinol Diabetes 2018;126(8):472-477.

25. Bordier L, Dolz M, Monteiro L, et al. Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. Front Endocrinol (Lausanne) 2016; 7:18.

26. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 2014;14(9):528.

27. Sone H, Mizuno S, Yamada N. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(18):1925-1927.

28. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995;122(8):561-568.

29. Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37(1):31-38.

30. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 2019;42(3):400-405.

31. Li F, Zhang Y, Li H, et al. TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. Diabetes Res Clin Pract 2020;166: 108289.

32. Yang J, Yang X, Zhao D, Wang X, Wei W, Yuan H. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. J Diabetes Investig 2021;12(5):828-836.
33. Shapiro ET, Polonsky KS, Copinschi G, et al. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 1991;72(2):444-454.

34. Guemes A, Cappon G, Hernandez B, et al. Predicting Quality of Overnight Glycaemic Control in Type 1 Diabetes Using Binary Classifiers. IEEE J Biomed Health Inform 2020;24(5):1439-1446.

35. Sheehan JP. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol Ther 2004;6(4):525-533.

36. Jin HY, Lee KA, Park TS. The impact of glycemic variability on diabetic peripheral neuropathy. Endocrine 2016;53(3):643-648.

37. Šoupal J, Škrha J Jr, Fajmon M, et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014;16(4):198-203.

**Figures**

![Figure 1](image-url)
Prevalence of sudomotor dysfunction in tertiles of time in range (a TIR1: TIR< 35.53%; TIR2 :35.53%≤TIR≤58.86%; TIR3: TIR>58.86%), time above range (b TAR1: TAR< 37.74%; TAR2 :37.74%≤TAR≤60.43%; TAR3: TAR>60.43%), nocturnal time in range (c NTIR1: nocturnal TIR< 47.94%; NTIR2: 47.94%≤ nocturnal TIR≤83.92%; NTIR3: nocturnal TIR>83.92%) and nocturnal time above range (d NTAR1: nocturnal TAR < 12.50%; NTAR2 :12.50%≤ nocturnal TAR ≤50.00%; NTAR3: nocturnal TAR >50.00%). Linear-by-linear association chi-square test was applied to determine the P value for trend.